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Neutrophils are the first and most numerous cells to arrive at
the site of an inflammatory insult and amongst the first to die.
We previously reported that alpha-defensins, released from apop-
totic human neutrophils, augmented the antimicrobial capacity
of macrophages whilst also inhibiting the biosynthesis of pro-
inflammatory cytokines. In vivo, alpha defensin administration
protected mice from inflammation, induced by thioglychollate in-
duced peritonitis or following infectionwith S. enterica serovar Ty-
phimurium. We have now dissected the anti-inflammatory mecha-
nism of action of themost abundant neutrophil α-defensin, Human
Neutrophil Peptide 1 (HNP1). Herein we show that HNP1 enters
macrophages and inhibits protein translation without inducing
the unfolded-protein response or affecting mRNA stability. In
a cell-free in vitro translation system, HNP1 powerfully inhib-
ited both cap-dependent and cap-independent mRNA translation,
whilst maintaining mRNA polysomal association. This is the first
demonstration of an eobiotic peptide released from one cell type
(neutrophils), directly regulating mRNA translation in another
(macrophages). By preventing protein translation, HNP1 functions
as a ‘molecular brake’ on macrophage driven inflammation; ensur-
ing both pathogen clearance and the resolution of inflammation
with minimal bystander tissue damage.
macrophages j α-defensins j mRNA translation j inflammation
Introduction
Neutrophils, via the release of key inflammatory mediators, con-
vey signals to practically all other immune cells, orchestrating
both the innate inflammatory and subsequent adaptive immune
responses (1). Through the de novo generation of lipid me-
diators they are also key players in the resolution of inflam-
mation [reviewed in (2)]. Following neutrophil apoptosis, their
subsequent uptake by human monocyte derived macrophages
(HMDMs) induces complex phenotypic changes, including the
release of the immunosuppressive cytokines IL-10 and TGF-β
[reviewed in (3)]. We previously reported that the human an-
timicrobial peptides, α-defensins, [which are released following
apoptosis, necrosis or NET-osis (4) of neutrophils] also inhibited
the secretion of multiple cytokines from activated HMDMs, for
up to 72 hours, with full recovery thereafter and no effect on cell
viability (5). In vivo, inmice, neutrophil derived α-defensins, given
at the time of inducing peritonitis led to a diminished inflam-
matory exudate (5). In addition mice infected with pathogenic
S. enterica ser. Typhimurium showed a reduced bacterial load
and serum TNFα levels upon administration of exogenous α-
defensin. Hence neutrophil-derived α-defensins, were able to
affect profound changes in the inflammatory environment whilst
also serving as effective anti-microbial peptides.
α-Defensins are small (3-4 kDa) cationic peptides that form
part of a larger family of defensins [that also includes beta and
theta peptides]. Four structurally related peptides (HNP1-4) exist
within the azurophil granules of neutrophils, of which HNP1 is
the most abundant (6-9). They share a similar triple-stranded β-
sheet structure, which is critically held together by three intra-
molecular disulphide bridges. Once the azurophil granules fuse
with phagosomes they release high concentrations of α-defensins
close to the pathogen surface, where their amphipathic nature
allows them to rapidly gain entry to the cell’s membrane (10). The
permeabilization of membranes by α-defensins is believed to be
crucial to their ability to kill microbes and host cells, elicited by
membrane disruption and leakage of cellular contents (9, 11). Im-
portantly however, α-defensins only kill proliferatingE. coli and a
simplemodel of ‘death by pore formation’ is inadequate to explain
all their antibacterial properties (12). They have also been noted
to inhibit bulk bacterial protein synthesis in E. coli, though this is
thought to be a consequence of membrane disruption and is tem-
porally associated with cell death (11, 12). Additionally following
HIV-1 infection, α-defensins play a crucial role in inhibiting their
life-cycle (13, 14), suggesting that they have at their disposal a
number of different mechanisms to kill diverse pathogens (7, 15).
In favour of this hypothesis is the observation that α-defensin
dimerization (which requires a tryptophan residue at position 26)
is vital for its ability to kill S. aureus (16), but has little effect on
its ability to kill E. coli (17).
Significance
Neutrophils are the major effectors of acute inflammation
responding to tissue injury or infection. The clearance of apop-
totic neutrophils by inflammatory macrophages also provides
a powerful pro-resolution signal. Apoptotic or necrotic neu-
trophils also release abundant amounts of the antimicrobial
peptides, alpha defensins. In this report we show that the
most abundant of these peptides, HNP1 profoundly inhibits
protein translation. It achieves this without affecting mRNA
stability or by preventing mRNA polysomal association. This
is the first demonstration of a peptide released from one
cell, a leukocyte, entering and directly modulating the trans-
latome of another cell. It alludes to a novel mechanism, driven
by dying neutrophils, that ensures the timely resolution of
macrophage driven inflammation, without compromising an-
timicrobial function.
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Fig. 1. HNP1 inhibits bulk protein synthesis, which
is dependent on HNP1 tertiary structure.(A-B) HNP1
treated HMDMswere stimulated with the TLR7 ligand
R848 (1μg/ml) (A) or with 3μg/mL CD40L + 5ng/mL
IFNγ (B) for 18 hrs. TNFα (A), IL6 and IL1β (B) were
assayed by ELISA. (C-D) HMDMs stimulated as for (A)
and treated with 12.5 μg/ml of HNP1 or the mutant
peptides LHNP, W26A or Melle at the same (C) or
variable concentrations (D). TNFα assayed by ELISA
after 18 hours. Representative of five independent ex-
periments. One way ANOVA with Dunnett’s multiple
comparison tests. ** P<0.01, * P<0.05. (E)Methionine
starved HMDMswere then cultured with 10μCi/mL 35S-
methionine +/- activation [with 3μg/mL CD40L and
5ng/mL IFNγ], and +/- addition of HNP1 (25μg/mL)
for 4 or 18 hours. Secreted and intracellular proteins
were resolved by SDS-PAGE. Phosphorimages of radi-
olabelled cellular and secreted protein gels show de
novo protein synthesis. (F) De novo protein synthesis
of 35S-Methionine labeled proteins following 18 hours
of culture, quantified by scintillation counting and
normalised to untreated controls. N=3. Error bars rep-
resent the mean ± SEM; ** P<0.01, * P<0.05 (Tukey’s
post hoc test following a one-way ANOVA).
Fig. 2. HNP1 enters HMDMs. Confocal microscopy images of HNP1 treated
HMDMs prior to visualization of anti-HNP1 (green) and DAPI (blue) seen on
the merged images. In addition, red secondary staining indicates calreticulin
(specific for the ER) in (A) and the ribosomal associated protein Rps20 in (B).
Representative images from 1 of 6 independent experiments. White size bars
indicate 60μm.
We wished to understand how α-defensins could simulta-
neously function as an effective antimicrobial antibiotic, whilst
also inducing profound changes in HMDM gene expression.
We report here that HNP1 enters HMDMs, where it pro-
foundly inhibits protein translation in both resting and activated
macrophages, without affecting mRNA stability or turnover. In-
stead it abrogates mRNA translation without affecting mRNA
polysomal association.
Results
HNP1 inhibits the synthesis of proteins, which is dependent
on HNP1 tertiary structure. We have previously shown that
whilst alpha defensins augmented the macrophage’s ability to
kill intracellular Pseudomonas aeruginosa, these peptides simul-
taneously inhibited the production of multiple cytokines (TNFα,
IL-6, IL-8 and IL-1β) (5). HNP1 also inhibited TNFα biosyn-
thesis from HMDMs stimulated with the toll-like receptor 7/8
(TLR7/8) agonist R848 [Fig 1A]. The biosynthesis of IL-6 and
IL-1β induced via the T cell surrogate stimulus CD40L/IFNγ,
was also reduced [Fig 1B], confirming that disparate stimuli and
multiple secreted proteins were susceptible to HNP1-mediated
inhibition. The structure of HNP1 was crucial for its cytokine
inhibitory potential. When the intra-molecular disulphide bonds
that stabilize the triple-stranded beta-sheet structure of HNP1
was disrupted (L-HNP), or when dimerization was prevented by
replacing the tryptophan residue at position 26 with the non-polar
amino acid alanine (W26A) (16), a complete loss of cytokine
inhibitory potential was seen [Fig 1C and (5)]. In contrast N-
methylation of Ile20 (Melle), (which also prevents dimerization),
had a minimal effect on the ability of HNP1 to inhibit R848-
induced TNFα production by HMDMs [Fig 1C and 1D].
To test if HNP1 might inhibit protein synthesis per se, stim-
ulated HMDMs were labelled with 35S-methionine in the pres-
ence of HNP1. 35S-methionine incorporation into proteins within
cellular lysates (i.e. cellular proteins) and the culture media (i.e.
secreted proteins) was visualised [Fig 1E] and quantified, fol-
lowing 18 hours of culture [Fig 1F]. Strikingly, HNP1 treatment
significantly reduced the quantity of both 35S-labelled cellular and
secreted proteins in un-stimulated HMDMs and robustly inhib-
ited the labelling of secreted proteins in CD40L/IFNγ stimulated
HMDMs, possibly reflecting the highly secretory phenotype of
the stimulated macrophage. As expected, secreted TNFα was
significantly reduced by HNP1 [Fig S1A]. However the overall
cellular protein levels were unchanged during the time-course
of the experiment [Fig S1B], consistent with a lack of increased
global protein turnover and with maintenance of cell number and
viability, as previously reported (5). Taken together neutrophil-
derived HNP1 profoundly inhibits global protein synthesis within
the resting or activated macrophage.
Exogenous HNP1 accumulates in the macrophage. HNP1
gained entry tomacrophages and was foundwithin themembrane
and cytoplasm. However there was no clear co-localisation of
HNP1 (or the control peptide W26A) with the ER marker cal-
reticulin [Figs 2A and Fig S2A and Fig S2C] or with ribosomes
[stained with anti Rps20, Figs 2B, Fig S2B and Fig S2D]. Control
experiments also showed no non-specific staining or cross reactiv-
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Fig. 3. . HNP1 binds to mRNA but does not affect mRNA stability. (A) Electrophoretic mobility shift assay. Poly(C)25 RNA oligonucleotide probe [10 pmoles]
incubated with molar ratios of HNP1 or W26A and RNA:peptide complexes resolved by non-denaturing acrylamide gel electrophoresis. * = free poly(C) probe,
arrowhead = non-specific complex. Error bars represent mean ± SD. (B) Binding of HNP1 and W26A to poly(C)25 RNA relative to total input RNA (where the
relative amount of free probe is given in arbitrary units) (C) RNA was extracted from CD40L/IFNγ stimulated HMDMs and mRNA of TNF-α, IL-10, tristetraprolin
(TTP) and cyclooxygenase 2 (Cox-2) was quantified by qRT-PCR and expressed as the ratio of mRNA from treated to untreated HMDMs. (D) Supernatants
were collected for the first 10 hours from cells treated as in (C) and TNFα protein assayed by ELISA. (E) TNFα mRNA levels were quantified from HMDMs that
had been treated with 12.5μg/mL of HNP1 or W26A, then stimulated with R848 (1μg/ml) for 1 hour before adding actinomycin D (5μg/mL).TNFα is expressed
relative to T = 0 min. Error bars are mean ± SEM for each time point and line represents a non-linear 2-phase decay fit with R2 values of 0.8667 and 0.8351
for W26A and HNP1 respectively. Results are derived from 3 separate experiments. A-D are representative of experiments repeated three times. (A-B) Tukey’s
post hoc test following a one-way ANOVA. ****P<0.0001 * P<0.03, (C-D) Tukey’s post hoc test following a two-way ANOVA. n.s = not significant, p = 0.094.
Fig. 4. . HNP1 does not cause ER stress. (A) R848 (1μg/ml) stimulated (u)
HMDMs with either 12.5µg/mL HNP1 (filled ∇) , L-HNP1(n) or 1µM thapsigar-
gin (<). Macrophage mRNA for CHOP, spliced XBP1 and BiP were quantified
by qRT-PCR and expressed relative to the same mRNA in untreated control
HMDMs. Hours represent time following stimulation N=3. Error bars= mean
± SD.
ity between HNP1 and the ER or ribosomal secondary antibodies
[Fig S3].
HNP1 binds non specifically to RNAbut does not altermRNA
transcription or stability. As HNP1 enters the macrophage it
may, by reason of its positive charge and amphipathic nature
(10, 18), bind to mRNA, so altering its turnover and inhibiting
protein synthesis. This was tested using electrophoretic mobility-
shift assays (EMSAs) with 25mer homopolymeric RNA oligonu-
cleotides. In contrast to W26A, HNP1 showed concentration-
dependent shifts of poly(C) [Fig 3A-B], poly(A) [Fig S4A-B] and
poly(U) RNA [Fig S4C-D], which was observed both in the pres-
ence or absence of Mg2+ [Fig S4E]; a cation often required for
nucleic acid binding by proteins. An antibody supershift EMSA
also confirmed that HNP1 could bind to mRNA (coding for the
firefly luciferase (fLuc) or β-galactosidase (β-gal) reporters) [Fig
S4F].
To ask if HNP1 affected mRNA transcription, we quanti-
fied the steady-state mRNA levels generated by CD40L/IFNγ
stimulated HMDMs. The mRNA levels of TNFα, IL-10, cy-
clooxygenase (Cox2) and tristetraprolin (TTP) were unaffected
by HNP1 treatment of HMDMs over a 24hr time course [Fig
3C], despite a clear reduction in TNFα protein production [Fig
3D]. To assess mRNA decay, HNP1 or W26A treated HMDMs
were stimulated (with R848) for 1 hour resulting in maximal
TNF-α mRNA levels, prior to the addition of actinomycin D to
arrest further transcription. The decay rate of TNF-α mRNA
was not significantly modulated in HNP1 versus W26A-treated
HMDMs over a further 1 hour time-course [Fig 3E]. As TNF-
α mRNA stability is mediated in part by the zinc-finger protein
TTP, which binds AU-rich sequences, we also assessed TNF-α
protein secretion from activated mouse bone marrow derived
macrophages (BMDMs), isolated from TTP deficient (TTP-/-)
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Fig. 5. HNP1 inhibits protein synthesis downstream of translation initiation.
(A) 1 ng m7G-fLuc-A0 reporter mRNA, translated in vitro using the RRL with
25 μg/mL [7.3μM] HNP1, LHNP1, W26A or vehicle control (0.01% acetic acid).
Translational output quantified as relative firefly luciferase activity (nor-
malised to vehicle control-treated samples). Error bars= mean ± SEM (n=3)
(B) As for (A) but relative m7G-luciferase-A0 reporter mRNA levels quantified
by qRT-PCR. Black bars represent pre-translation levels and white bars the
post translation levels. A representative experiment of n=3 experiments. (C)
As for (A), 400 pg m7G-fLuc-A0 reporter mRNA translated in the presence of
increasing concentrations of HNP1. The IC 50 (shown by the dotted line) is
1.6+/-0.02μM.Mean ± SEM from two independent experiments. (D) 1ng CSFV
IRES-β-gal-A0 reporter mRNAwas in vitro translated as for (A). Values plotted
relative to vehicle control. (n=3)Error bars represent mean ±SEM (n=3).for A
and D: ***P<0.001, *P<0.05 (analysed by Tukey’s multiple comparison post
hoc test following one-way ANOVA). (E) 1ng CrPV IRES-β-gal-A0 reporter
mRNA translated as in (A). ****P<0.0001, analysed by unpaired T test. Values
are plotted relative to vehicle control. (F) RRL was pre-treated with 150μg/mL
cycloheximide and either 25 μg/mL HNP1 or vehicle control. 1ng 32P-labelled
m7G-fLuc-A0 reporter mRNA was then added for the indicated times (shown
in minutes) prior to 15-30% sucrose density gradient fractionation. Graph
depicts the relative amounts ofmRNA sedimentingwith initiating ribosomes,
normalised to amount recruited at 5min in vehicle control-treated RRL. Black
bars are control and grey bars are HNP1 treated. Error bars represent mean
±SEM (n=3), *P<0.05 (unpaired t test).
mice or wild-type littermate controls. Again, HNP1 (but not L-
HNP1)was still able to significantly inhibit the secretion of TNF-α
from TTP-/- BMDMs [Fig S4G]. Taken together these data show
that HNP1 can bind to RNA, likely in a sequence-independent
manner, but does not affect mRNA stability or turnover.
HNP1 does not induce ER stress.We have previously shown
thatHNP1 does not inhibit the exocytosis of TNFα fromHMDMs
(5). We also wished to confirm that it did not prevent pro-
tein synthesis by inducing the unfolded protein response [UPR]
[reviewed in (19)]. In contrast to the positive control thapsigargin
(TG), we did not detect an increase in the synthesis of glucose-
regulated protein 78 (Grp78), X box-binding protein (XBP1) or
CCAAT/enhancer-binding protein homologous protein (CHOP)
in HNP1 treated and stimulated HMDMs [Fig 4], despite a clear
inhibition of R848-induced TNFα production at 6 and 24 hours
[Fig S5A]. Hence the profound inhibition of protein synthesis by
HNP1 was not the result of an induced UPR.
HNP1 does not block translation initiation. To ask if HNP1
affected translation directly, and to avoid the confounding effects
of mRNA transcription, processing or nuclear export, we utilised
the cell-free rabbit reticulocyte lysate (RRL) in vitro translation
system. Translation of the canonical fLuc reporter mRNA, was
profoundly inhibited in the presence of HNP1, but not by the
mutant control peptides, L-HNP nor W26A [Fig 5A]. As with
TNFα mRNA, HNP1 did not destabilise the reporter mRNA
because input mRNA levels were maintained [Fig 5B]. The IC50
value for this effect was approximately 1.6μM (or 5.5μg/ml) [Fig
5C], a concentration that significantly reduces the production
of pro-inflammatory cytokines from stimulated HMDMs in vitro
[Fig 1].
Eukaryotic mRNA has a 5’ monomethylated cap structure
(m7G) which is crucial for canonical translation initiation, the
rate-limiting and primary node of translation regulation (re-
viewed in (20)). To interrogate the role of translation initiation
in HNP1-mediated inhibition we employed reporter mRNAs
that contained a viral internal ribosome entry site (IRES) in
their 5’ untranslated regions (5’UTR), bypassing some or all of
the eukaryotic translation initiation factor (eIF) requirements
and initiating translation cap-independently (reviewed in (21)).
The Classical Swine Fever Virus (CSFV) IRES mRNA reporter
initiates translation independently of the majority of eIFs but is
dependent on the ternary complex (eIF2,GTP and tRNAi), whilst
the Cricket Paralysis Virus (CrPV) IRES allows the direct assem-
bly of the 80S ribosome at the start codon, bypassing all canonical
initiation factor requirements (22). Remarkably, despite their
diverse mechanisms of translation initiation, HNP1 was also able
to prevent the synthesis of both the CSFV-driven translation of β-
Gal [Fig 5D] and theCrPV-driven translation ofRenilla luciferase
(RLuc) [Fig 5E]. As HNP1 is able to prevent the translation of
mRNAs utilising diverse mechanisms of translation initiation it is
most likely that it is acting downstream of this point. To confirm
this empirically, ribosomal recruitment onto a radiolabelledm7G-
capped fLuc reporter mRNA was quantified in the presence
of cycloheximide, to halt the 80S ribosome at the start codon,
preventing translation elongation. Whilst HNP1 weakly inhibited
translation initiation at 5 minutes following mRNA addition, by
10minutes similarmaximal 80S recruitment to that seen in vehicle
control-treated extracts was observed [Fig 5F], indicating only a
small reduction in the rate of 80S recruitment in the presence of
HNP1 and supporting the conclusion that HNP1 predominantly
inhibits mRNA translation post-initiation.
HNP1 does not affect ribosomal association with mRNA. Fi-
nally to ask if luciferase mRNAwas maintained on polysomes de-
spite its significantly reduced translation, we assessed the steady-
state ribosomal association of m7G-fLuc mRNA in the presence
or absence of HNP1. Despite utilising a concentration of HNP1
that profoundly inhibited reporter protein synthesis [Fig 1E], we
observed no change in the polysomal profile [Fig 6A] or the
distribution of m7G-fLuc mRNA across the polysomal region
of the density gradient (fractions 4-10) [Fig 6B]. In contrast,
the presence of EDTA resulted in polysomal dissociation and
depletion of the reporter mRNA from the fractions containing
translating mRNA [Fig 6B and S5B]. We also wished to confirm
if a similar mode of action was seen in HMDMs, that had been
treated with HNP1 or vehicle control (for 18 hours). HMDMs
so treated were then stimulated with R848 for two hours to up-
regulate the synthesis of TNFα. Again, the bulk polysome profile
for HNP1 treated HMDMs was similar to that of control stim-
ulated cells [Fig 6C]. Importantly, the polysomal association of
TNFαmRNA in untreated orHNP1-treated stimulatedHMDMs
was not significantly altered [Fig 6D], despite the significant inhi-
bition of TNFα protein synthesis [Fig S5C]. This data confirms
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Fig. 6. HNP1 has no effect on polysome profile.
(A) RRL pre-treated with 25 μg/mL HNP1 or vehicle
control. 2ng 32P-labelled m7G-fLuc-A0 reporter mRNA
translated for 30 min prior to addition of 150μg/mL
cycloheximide or 25mM EDTA and 10-50% sucrose
density gradient fractionation. Solid black line = vehi-
cle control-treated, broken black line = HNP1-treated,
dotted grey line = EDTA-treated. (B) Relative reporter
mRNA content of gradient fractions expressed as a
percentage of the total input mRNA. Solid black line
with squares = vehicle control-treated, broken black
line with triangles = HNP1-treated, dotted grey line
with filled circles = EDTA-treated. (C) HMDMs treated
25 μg/mL HNP1 or vehicle control prior to R848 stimu-
lation for 2 hours. 150μg/mL cycloheximide added for
10 minutes prior to lysis and 10-50% sucrose density
gradient fractionation. Abs254nm trace to determine
sedimentation of 80S ribosome and polysomes. Solid
black line = vehicle control-treated, dotted line =
HNP1-treated. (D)TNFα mRNA content of gradient
fractions expressed relative to maximal TNFα mRNA
detected in fractions 3-10 (43S/60S to polysomal).
Solid black line = vehicle control-treated, broken black
line = HNP1-treated, error bars represent mean ±SD
(n=4); paired t test, no significant differences de-
tected.
that whilst HNP1 profoundly alters protein translation at a point
after translation initiation, it does not prevent mRNA polysomal
association.
Discussion
Cells of the immune system have developed tightly regulated
systems to ensure the timely resolution of inflammation. The
control of mRNA translation is emerging as a major mechanism
that regulates the levels of proteins within leukocytes [reviewed
in (23, 24)]. We have now identified a novel mechanism in which
themost abundant neutrophil α-defensin, HNP1, [which is readily
released as these cells die (5)], inhibits bulk protein translation
within macrophages. Whilst the characteristic hydrophobic, am-
phipathic nature of α-defensins allows them to partition into
the membrane lipid layer (25), it also ensures ready access to
the cell’s interior. Confocal imaging showed that HNP1 entered
macrophages [Fig 2], without inducing an unfolded protein re-
sponse [Fig 4] or affecting mRNA stability [Fig 3]. To our knowl-
edge this is the first description of an eobiotic peptide released
by one cell profoundly affecting the translational capacity of an-
other, in the absence of a requirement for de novo transcription,
and without compromising antimicrobial function.
HNP1 was able to inhibit translation initiated via diverse
mechanisms. Both canonical cap-dependent [Fig 5] and non-
canonical, cap-independent translation (driven by either a CSFV
or CrPV IRES) were profoundly inhibited in vitro. However the
small inhibitory effect of HNP1 on translation initiation [Fig 5F]
was insufficient to explain the magnitude of the effects seen
in vitro and within macrophages. Rather, the dramatic inhibi-
tion of CrPV IRES-driven translation, which dispenses with the
initiation event implicates an HNP1-mediated inhibition, down-
stream of translation initiation. HNP1 could inhibit translation by
binding non-specifically to mRNA or equally it could sequester
factors essential for translation, such as tRNA or ribosomal pro-
tein and/or rRNA components. Previous reports point to several
RNA-binding proteins that require a net positive charge and
arginine side chains (18). α-Defensins also possess 4 positively-
charged arginines, that might allow it to interact with RNA [Fig
3]. These side chains are important for its function, as the substitu-
tion of these amino acids for similarly charged lysine, significantly
reduces its bactericidal activity [(17, 26) and reviewed in (10)].
Considering the ability of HNP1 to kill a diverse array of bacterial
and viral pathogens, it will be of interest to determine whether
HNP-1 can similarly prevent prokaryotic protein translation.
Since HNP1 binds non-specifically to RNA we asked if it
could inhibit translation by modulating ribosome engagement
with mRNA. However both reporter and cellular mRNAs re-
mained polysome-associated [Figs 5 and 6] and the polysomal
distribution of these mRNAs were similar in control and HNP1-
treated RRL and HMDMs. Translational repression could be
occurring via either elongation and/or termination (27) and we
would speculate that HNP1 prevents translation elongation (22),
which has recently been established as a major control point for
protein synthesis (30).
Previous studies also allude to the greater importance of
protein synthesis rate over degradation rate in determining over-
all protein levels (28, 29). However, the lack of a significant
change in overall HMDM cellular protein level [Fig S1B] ar-
gues against an HNP1 mediated increase in non-specific cellular
protein degradation. Further, HNP1 profoundly inhibits reporter
protein synthesis in cell-free assays in which protein turnover
pathways are fundamentally compromised andHNP1 itself has no
known protease activity. Taken altogether we believe these data
indicate that HNP1 affects de novo protein synthesis.
The tertiary structure of monomeric HNP1 is also clearly
important for translational inhibition, as highlighted by the loss
of efficacy observed for linearized HNP1 (L-HNP1) or W26A
[Fig 1C]. However, the N-methylation of HNP1 Ile-20 (Melle),
which prevents dimerization, does not alter the ability of Melle to
inhibit TNF-α production, confirming that HNP1 dimerization is
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not required to inhibit macrophage protein translation [Fig 1D].
The concentration ofHNP1-3 in the synovial fluid of patients with
rheumatoid arthritis is between 3 and 25 μg/ml, with an average
of 12.4 μg/ml, suggesting that the concentration reached in tissues
is similar to that used in our assays (5). Our previous studies
have shown that HMDMs fully recover their pro-inflammatory
potential within 72 hours following exposure to α-defensins; so
whilst they clearly disable themacrophage protein translationma-
chinery, they do not inducemacrophage apoptosis (5). A previous
study reported that α-defensins reduced the release of IL1β from
activatedmonocytes, whilst not affecting the transcription of IL1β
mRNA (30). Based on our findings, these observations can likely
be explained by the translation of pro-IL1β being impaired.
In summary we have uncovered that neutrophil α-defensins
abrogate the bulk mRNA translation of proteins within HMDMs,
without affecting mRNA transcription or stability. In this way
they prevent an excessive pro-inflammatory response that would
create its own collateral damage, whilst still acting as powerful
antimicrobial peptides. This is the first demonstration of an
anti-microbial peptide that also has a translation-based anti-
inflammatory role, acting as a ‘molecular brake’. It opens the way
forward to developing similar peptide-based therapeutics that
would act as effective combined anti-inflammatory and antimi-
crobial agents.
Materials and Methods
All materials and the following protocols and are fully described in the SI
Appendix. Briefly, synthetic HNP1 and mutant derivatives were prepared by
solid-phase synthesis as previously described (31). Template plasmids pCSFV-
lacZ (32), pT7-Luc (33) for reporter mRNA transcription were previously
described and pSL200-CrPV-RLuc, Renilla luciferase downstream of a Cricket
Paralysis Virus (CrPV) IRES, was a kind gift from Matthias Hentze (EMBL,
Heidelberg). Healthy donor peripheral blood mononuclear cells (PBMCs)
were purified from whole blood as previously described (5). Stimuli in-
cluded 1μg/mL R848 (Invivogen), 3μg/mL CD40L (Peprotech) and 5ng/mL
IFNγ (Peprotech). Cytokines were quantified by sandwich ELISA (R&D Sys-
tems). For assessment of protein synthesis HMDMs were incubated in L-
Methionine-free DMEM (MP Biomedicals) for 2 hours at 37°C, 5% CO2
followed by 10μCi/mL 35S-Methionine (Perkin Elmer), stimulation with CD40L
and IFNγ and defensin peptides. In vitro transcription was assessed by m7G-
or ApG-capped, nonadenylated, 32P-UTP-labelled or non-labelled reporter
mRNAs were synthesised as previously described (35). In vitro translationwas
assessed using the nuclease-treated rabbit reticulocyte lysate (RRL) in vitro
translation kit (Promega) according to manufacturers’ recommendations.
For electrophoretic mobility shift assays 10 pmoles 5’-Cy5 labelled 25mer
oligonucleotide (poly-Adenine, poly-Cytosine or poly-Uracil) (Eurogentec)
was incubatedwithHNP1 orW26Apeptide in 10μL binding and then resolved
by electrophoresis. For immunocytochemistry HMDMs were grown on glass
coverslips and stained with mouse monoclonal anti-human HNP1-3 antibody
together with polyclonal rabbit anti-human ribosomal protein rps20 (Abcam,
dilution 1:250) or polyclonal rabbit anti-human calreticulin (Abcam, dilution
1:250). ER stress and the UPR, the mRNA stability assay along with RNA
quantitation and polysome analysis are fully explained in the supplemental
Materials and Methods section.
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